The Molecular Characterization of Multiple Myeloma at Relapse

Summary

Observational study investigating prognostic factors in newly diagnosed and relapsed multiple myeloma patients by use of clinical data, biochemical markers (blood samples), cytogenetic markers and gene expression profiling (myeloma cells from fresh bone marrow samples). Enabling future genetic studies by establishing a biobank of bone marrow and peripheral blood samples.

Conditions

• Multiple Myeloma

Interventions

PROCEDURE

Bone marrow examination

7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.

PROCEDURE

Blood samples

24 ml of cubital vein blood drawn in addition to diagnostic samples.

Sponsors & Collaborators

• Herlev Hospital

  collaborator OTHER

• Zealand University Hospital

  collaborator OTHER

• Naestved Hospital

  collaborator OTHER

• Agnes og Poul Friis Fond

  collaborator UNKNOWN

• Carl og Ellen Hertzs Legat til Dansk Læge- og Naturvidenskab

  collaborator UNKNOWN

• Dagmar Marshalls Fond

  collaborator UNKNOWN

• Danish Cancer Research Foundation

  collaborator OTHER

• Direktør Jacob Madsen og hustru Olga Madsens Fond

  collaborator UNKNOWN

• Elna og Jørgen Fagerholt Pedersens Kræftforskningsfond

  collaborator UNKNOWN

• Eva og Henry Frænkels Mindefond

  collaborator OTHER

• Manufacturer Einar Willumsen's memorial team

  collaborator OTHER

• Fonden til Lægevidenskabens Fremme

  collaborator OTHER

• Grosserer M. Brogaard og Hustrus Mindefond

  collaborator UNKNOWN

• Højmosegård-Legatet

  collaborator UNKNOWN

• Janssen-Cilag, S.A.

  collaborator INDUSTRY

• Karen A. Tolstrups fond

  collaborator UNKNOWN

• Krista og Viggo Petersens Fond

  collaborator UNKNOWN

• Købmand Sven Hansen og hustru Ina Hansens Fond

  collaborator UNKNOWN

• Meta og Håkon Baggers Fond

  collaborator UNKNOWN

• Reinholdt W. Jorck og hustrus Fond

  collaborator UNKNOWN

• Rigshospitalet, Denmark

  lead OTHER

Principal Investigators

• N Emil U Hermansen, MD · Rigshospitalet, Denmark

• Peter Gimsing, MD, DMSc · Rigshospitalet, Denmark

• Annette J Vangsted, MD, DMSc · Zealand University Hospital

• Mette K Andersen, MD, DMSc · Rigshospitalet, Denmark

• Finn C Nielsen, MD, DMSc · Rigshospitalet, Denmark

• Dan Kristensen, MD · Naestved Hospital, Denmark

• Nielsaage T Clausen, MD · Herlev Hospital

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2008-03-31

Primary Completion

2014-12-31

Completion

2014-12-31

Countries

• Denmark

Study Locations